Review Article

Biomarkers in Cardiorenal Syndromes

Shihui Fu,1,2 Shaopan Zhao,1 Ping Ye,1 and Leiming Luo1

1Department of Geriatric Cardiology, Chinese People’s Liberation Army General Hospital, Beijing 100853, China
2Department of Cardiology and Hainan Branch, Chinese People’s Liberation Army General Hospital, Beijing 100853, China

Correspondence should be addressed to Ping Ye; sci301@126.com and Leiming Luo; lleim@sina.com

Received 11 December 2017; Revised 10 January 2018; Accepted 1 February 2018; Published 5 March 2018

There is a consensus that cardiorenal syndromes (CRS) are defined as the disorders of heart and kidney where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in another. Patients with CRS have increased hospitalization and mortality rates, and thus their identification is of great implication. Biomarkers are not only predictive in heart failure or renal diseases, but also useful in identifying cardiac dysfunction in renal diseases and renal injury in heart failure. Thus, they may be applied in order to identify patients with CRS and even assess prognosis and guide therapy in these patients. However, studies on biomarkers have just begun in CRS. Future studies are essential to observe current biomarkers and find novel biomarkers in CRS so as to improve diagnosis, therapy, and prognosis of CRS.

1. Introduction

There is a consensus that cardiorenal syndromes (CRS) are defined as the disorders of heart and kidney where acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in another [1]. They include five subtypes: (1) type 1 (acute cardiorenal syndrome), acute heart failure (AHF) leading to acute kidney injury (AKI) mediated by hemodynamic, humoral, hormonal, and immune factors; (2) type 2 (chronic cardiorenal syndrome), chronic heart failure (CHF) leading to chronic kidney disease (CKD) mediated by low cardiac output, chronic hypotension, increased venous pressure, subclinical inflammation, endothelial dysfunction, and accelerated atherosclerosis; (3) type 3 (acute renocardiac syndrome), AKI leading to AHF mediated by vasoconstriction, volume expansion, humoral signaling, electrolyte abnormalities, coagulation imbalance, activated renin-angiotensin-aldosterone system (RAAS), and sympathetic nervous system (SNS); (4) type 4 (chronic renocardiac syndrome), CKD leading to CHF mediated by anemia, malnutrition, Na-H2O overload, uremic toxins, Ca/P abnormalities, and chronic inflammation; (5) type 5 (secondary CRS), systemic conditions leading to simultaneous dysfunction of the heart and kidney mediated by hemodynamic changes, neurohumoral activation, and altered metabolism and immune response [1]. Patients with CRS have increased hospitalization and mortality rates, and thus their identification is of great implication [2]. Biomarkers are not only predictive in heart failure (HF) or renal diseases, but also useful in identifying cardiac dysfunction in renal diseases and renal injury in heart failure. Thus, they may be applied in order to identify patients with CRS and assess prognosis and guide therapy in these patients (Table 1) [1, 2].

2. Cardiac Biomarkers

2.1. Cardiac Troponin. As the components of the contractile apparatus in cardiomyocytes, cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are specific biomarkers of myocardial injury and infarction [3]. cTnT and cTnI correlate with ventricular remodeling after HF and increase as HF progresses and mortality rises [4]. Abnormal hemodynamics (ventricular overload and hypertrophy) and neuroendocrine (activated RAAS and SNS) result in cardiomyocyte necrosis and apoptosis and elevated cTnT and cTnI levels in patients with HF [5]. cTnT and cTnI predict prognosis and stratify risk in patients with HF [6]. Patients with CKD have elevated cTnT and cTnI levels because of the reduced excretion from the kidney [7]. cTnT and cTnI predict cardiovascular and all-cause mortality rates in patients with mild-to-moderate CKD or end-stage renal disease (ESRD) [8]. Elevated cTnT

Hindawi BioMed Research International Volume 2018, Article ID 9617363, 8 pages https://doi.org/10.1155/2018/9617363
Table 1: Biomarkers in cardiorenal syndromes.

| Syndromes                        | Biomarkers                          | References                                      |
|----------------------------------|-------------------------------------|------------------------------------------------|
| Acute cardiorenal (type 1)       |                                     |                                                 |
| Cardiac                          | cTnT, BNP, NT-proBNP, MPO, MR-proADM | Ronco et al. [1]; Klip et al. [44]              |
| Renal                            | Creatinine, cystatin C, NGAL, KIM-1, NAG, IL-18 | Ronco et al. [1]                              |
| Chronic cardiorenal (type 2)     |                                     |                                                 |
| Cardiac                          | BNP, NT-proBNP, CRP, ST2            | Ronco et al. [1]; Daniels and Bayes-Genis [38] |
| Renal                            | Creatinine, microalbuminuria, cystatin C, CRP, homocysteine, uric acid, urotensin II, aldosterone | Ronco et al. [1]; Iacoviello et al. [48]; Fox et al. [49]; Garoufi et al. [50] |
| Acute renocardiac (type 3)       |                                     |                                                 |
| Cardiac                          | BNP, NT-proBNP                      | Ronco et al. [1]                               |
| Renal                            | Creatinine, cystatin C, NGAL, KIM-1, NAG, IL-18 | Ronco et al. [1]                              |
| Chronic renocardiac (type 4)     |                                     |                                                 |
| Cardiac                          | BNP, NT-proBNP, CRP                 | Ronco et al. [1]                               |
| Renal                            | Creatinine, microalbuminuria, cystatin C, homocysteine, uric acid, urotensin II, aldosterone | Ronco et al. [1]; Iacoviello et al. [48]; Fox et al. [49]; Garoufi et al. [50] |
| Secondary CRS (type 5)           |                                     |                                                 |
| Cardiac                          | BNP, CRP, procalcitonin, ST2        | Ronco et al. [1]; Daniels and Bayes-Genis [38] |
| Renal                            | Creatinine, NGAL, IL-18, KIM-1, NAG  | Ronco et al. [1]                               |

BNP: B-type natriuretic peptide; cTnT: cardiac troponin T; IL-18: interleukin-18; KIM-1: kidney injury molecule-1; MPO: myeloperoxidase; MR-proADM: midregional proadrenomedullin; NAG: N-acetyl-β-D-glucosaminidase; NGAL: neutrophil gelatinase-associated lipocalin; NT-proBNP: N-terminal proBNP.

and cTnT levels are related to myocardial injury, ventricular hypertrophy, HF, and CKD, and there are more individuals with elevated cTnT and cTnI levels due to the use of high-sensitivity assays in the general population [9]. Regardless of using a high-sensitivity assay or not, cTnT and cTnI predict hospitalization and mortality rates in the general population.

2.2. B-Type Natriuretic Peptide. B-type natriuretic peptide (BNP) is mainly released from cardiomyocytes and plays diuretic, natriuretic, vasodilative, and other cardioprotective roles. Patients with HF have overactivated RAAS and SNS and compensated release of BNP due to ventricular volume and pressure overload. But BNP is still deficient and its roles are resisted in these patients [10]. As two preferred biomarkers of HF, BNP and N-terminal proBNP (NT-proBNP) correlate with HF symptom [New York Heart Association (NYHA) classification], cardiac function [left ventricular ejection fraction (LVEF)], ventricular pressure, and wall thickness. BNP and NT-proBNP are elevated in patients with HF, and they help assess prognosis and stratify risk in these patients [11]. BNP and NT-proBNP have superior abilities to predict prognosis compared with traditional cardiovascular risk factors, including age, NYHA classification, ventricular dilation, and renal dysfunction, and neuroendocrine indicators, including norepinephrine, renin, angiotensin, aldosterone, and endothelin [12, 13]. BNP and NT-proBNP assess severity and assess prognosis in patients with systolic or diastolic dysfunction. Moreover, repeated BNP and NT-proBNP assays can provide more information on risk stratification. BNP and NT-proBNP predict cardiovascular events in the general population [14]. BNP has been considered to guide therapy and assess its effects, and BNP-guided therapy may reduce all-cause mortality rates in patients with HF [15]. However, the benefit of BNP-guided therapy in HF is based on relatively low-quality evidence and not completely established as a standard method. Future models based on BNP and NT-proBNP may benefit diagnosis and therapy of patients with HF [16]. Patients with renal dysfunction have reduced excretion of BNP and NT-proBNP from the kidneys. BNP and NT-proBNP correlate with renal function and predict cardiovascular and all-cause mortality rates, independent of cardiovascular diseases and their severity [17]. NT-proBNP is more sensitive to renal function than BNP [18]. Relative effects of heart and kidney on plasma BNP and NT-proBNP levels remain unclear in patients with CRS [19]. Kidneys may play a more significant role than the heart in patients with ESRD, and the heart may play a more significant role than the kidneys in other patients with CKD.

2.3. C-Reactive Protein. As a biomarker of systematic inflammation, C-reactive protein (CRP) may affect endothelial dysfunction through increasing expression of endothelial cell adhesion molecules, decreasing nitric oxide and prostaglandin released from endothelial cells, augmenting low-density lipoprotein uptake by macrophages, and inducing complement-mediated inflammatory reaction [20]. Moreover, CRP may affect coagulative and fibrinolytic systems and inhibit ventricular function. CRP has elevated levels and predicts prognosis in patients with cardiac or renal dysfunction [21, 22]. Compared with traditional cardiovascular risk
factors, CRP has an additional ability to predict cardiovascular risk in the general population [23]. Plasma CRP levels correspond to the following cardiovascular risk: low risk (<1 mg/L), middle risk (1–3 mg/L), high risk (>3 mg/L), and extremely high risk (>10 mg/L) [24]. Plasma CRP levels >2 mg/L predict increased death risk in the general population [25]. CRP is related to both microalbuminuria and macroalbuminuria. CRP increases glomerular capillary permeability and glomerular mesangial cell hyperplasia through mediating vasoconstriction, embolism, and inflammation. CRP predicts prognosis and stratifies risk in patients with ESRD [26].

2.4. Myeloperoxidase. Myeloperoxidase (MPO) is produced by neutrophils and monocytes. A series of reactive oxidation substances are produced by MPO catalysis [27]. MPO is related to oxidative stress, inflammatory reaction, ventricular remodeling, vulnerable plaque, and metabolism of muscle cells [28]. MPO predicts prognosis in patients with AHF, independently of traditional cardiovascular risk factors. Moreover, MPO has elevated levels in patients with CHF and can identify patients with CHF in the general population. Regardless of systolic or diastolic HF and left or right HF, plasma MPO levels positively correlate with CHF progression and predict cardiovascular events in patients with CHF [29]. MPO also predicts CKD severity and mortality rates in patients with CKD [30].

2.5. Soluble Vascular Endothelial Growth Factor Receptors-1. Vascular endothelial growth factor (VEGF) promotes the growth of endothelial cells and prevents apoptosis of endothelial cells and increases nitric oxide and prostaglandin released from endothelial cells. VEGF, platelet-derived growth factor (PDGF), and soluble vascular endothelial growth factor receptors-1 (sFlt-1) have elevated levels in patients with HF. PDGF reduces infarct size and improves cardiac dysfunction, whereas sFlt-1 may inhibit these roles of PDGF. sFlt-1 is a biomarker that predicts prognosis in patients with HF [31]. VEGF may identify the development of CKD and predict mortality in patients with CKD. sFlt-1 contributes to endothelial dysfunction in CKD and links microvascular disease with HF in CKD [32]. The ratio of PDGF to sFlt-1 correlates with HF severity in patients with renal dysfunction.

2.6. Copeptin. Copeptin, a glycosylated 39-amino-acid peptide, is a C-terminal part of precursor pre-provasopressin (pre-proAVP) and is released in the same amount as AVP. Whether the heart also releases copeptin into the blood remains controversial [33]. AVP has a half-life of 5–20 minutes, whereas copeptin has a half-life of days [34]. Copeptin takes place of AVP as a reliable biomarker of cardiovascular diseases as well as a significant predictor of mortality [35]. It has been regarded as a hallmark of activated hypothalamo-pituitary-adrenals axis and thus received main attention as a marker of AHF and AKI.

2.7. ST2. As a member of the interleukin-1 receptor family, ST2 exists in two different forms: a transmembrane receptor (ST2L) and a soluble decoy receptor (sST2) [36]. It affects the activation of T-helper type 2 (Th2) cells and production of Th2-related cytokines [37]. sST2 has been reported to correlate with cardiovascular events and mortality in patients with AHF and CHF [38–40]. sST2 is significantly related to cardiovascular and all-cause mortality in low-risk populations [41]. sST2 improves prognostic prediction in HF patients with renal dysfunction. Moreover, sST2 is linked to the development of CKD and is associated with cardiovascular events and survival in patients with CKD.

2.8. Midregional Proadrenomedullin. Adrenomedullin (ADM), a 52-amino-acid ringed peptide with C-terminal amidation, is a potent vasodilator synthesized in the adrenal medulla, vascular endothelial cells, heart, and elsewhere in response to physical stretch and specific cytokines [42]. Plasma ADM levels are elevated in the heart as a result of pressure and volume overload. It is difficult to measure plasma ADM levels due to its short half-life and existent binding proteins. Midregional proadrenomedullin (MRproADM) is more stable and is manufactured in a 1:1 ratio with active ADM [43]. MRproADM is a promising biomarker, identifying global disease burden in HF and predicting morbidity in patients with HF [44]. MRproADM correlates with the development of CKD and predicts the decline of renal function. MRproADM is associated with cardiovascular and all-cause mortality in patients with renal dysfunction.

2.9. Procalcitonin. Procalcitonin is a precursor peptide of hormone calcitonin, and its levels increase particularly following bacterial infection. Procalcitonin has been studied from two perspectives: as a prognostic marker in HF and as a guiding biomarker for adequate therapy [45]. Inflammation is an important pathophysiological factor in HF and may affect prognosis of patients with HF. Patients with HF have significantly higher plasma procalcitonin levels than healthy subjects, and plasma procalcitonin levels are associated with severity of HF. Procalcitonin is associated with mortality and rehospitalization in HF patients with no evidence of infection. Meanwhile, procalcitonin can be applied to guide decision-making with respect to antibiotic therapy in patients with AHF by identifying patients with concomitant or triggering bacterial infection. Procalcitonin-guided antibiotic treatment reduces the duration of antibiotic therapy and improves outcomes in HF patients [46]. Moreover, serum procalcitonin levels are associated with AKI, and elevated procalcitonin levels identify patients at increased risk of AKI [47].

3. Renal Biomarkers

3.1. Creatinine. As standard indicators of renal function, serum creatinine levels and glomerular filtration rate (GFR) are vital for effective identification of renal diseases and prognostic prediction of patients with renal diseases. Both HF and renal diseases play important roles in the occurrence and progression of each other and lead to increased prevalence and mortality of patients with HF and renal diseases. Thus,
creatinine can be applied to identify increased prevalence of renal diseases in patients with HF and predict increased mortality in patients with either HF or renal diseases.

3.2. Microalbuminuria. Microalbuminuria is related to not only HF and CKD development, but also rehospitalization and mortality rates in the general population [48]. Microalbuminuria predicts prognosis and stratifies risk in patients with HF, independently of GFR and traditional cardiovascular risk factors. However, the mechanisms linking microalbuminuria to HF remain unclear. Microalbuminuria reflects hemodynamic and neuroendocrine interaction of renal tubules and glomerulus with cardiac muscles and vessels and indicates extensive vascular injury caused by cardiovascular risk factors (insulin resistance, blood pressure, glucose, lipids, inflammation, and coagulative abnormality) [51]. Microalbuminuria is a biomarker of endothelial function, vascular permeability, arterial stiffness, and hemodynamic stability in the general population [52]. Angiotensin converting enzyme inhibitor and angiotensin receptor antagonist reduce cardiovascular events and deaths and delay the deterioration of renal function by decreasing microalbuminuria in the general population.

3.3. Neutrophil Gelatinase-Associated Lipocalin. Neutrophil gelatinase-associated lipocalin (NGAL) is produced by neutrophils due to an inflammatory reaction. NGAL has elevated levels because of the acute renal tubular injury caused by ischemia and toxins. NGAL identifies patients with AKI and serves as a biomarker of AKI. NGAL is a biomarker of CKD and renal transplantation therapy and correlates with residual renal function in patients on dialysis [53]. NGAL predicts worsening renal function, correlates with inflammatory reaction, and mediates ventricular remodeling in AHF [54]. NGAL is produced due to renal injury and inflammatory reactions and serves as a biomarker in parallel with NYHA classification to predict mortality rates in patients with CHF [55].

3.4. Cystatin C. As an inhibitor of cysteine protease, cystatin C is initially produced by nuclear cells and is completely filtered and reabsorbed by the kidneys. Cystatin C is not affected by age, sex, race, or muscle volume and can serve as a better biomarker of AKI, CKD, and renal replacement therapy than creatinine [56]. Elevated cystatin C levels suggest the existence of renal dysfunction in patients without CKD based on GFR and microalbuminuria [57]. Cystatin C is related to not only HF progression, but also cardiovascular events and deaths, independently of renal function, in patients with HF [3]. Cystatin C correlates with cardiac function and structure, as well as NT-proBNP, in patients with HF, and is a biomarker of ventricular hypertrophy in patients with hypertension [58].

3.5. Kidney Injury Molecule-1. As a transmembrane protein in epithelial cells of renal proximal convoluted tubules, kidney injury molecule-1 (KIM-1) increases because these cells are injured by ischemia or toxicosis [59]. KIM-1 may play protective roles (preventing tubule blocking and inhibiting inflammatory reaction) at the early stage of renal injury and harmful roles (promoting epithelial hyperplasia and aggravating interstitial fibrosis) at its later stage. KIM-1 is a biomarker of renal injury to assess the injury degree and observe the therapeutic effect [54]. KIM-1 identifies patients with AKI or CKD significantly earlier than creatinine, and it predicts prognosis in patients with AKI or CKD. Moreover, KIM-1 identifies the development of AKI or CKD in patients with HF. KIM-1 is elevated in patients with HF and is related to the development of HF. KIM-1 is associated with increased HF, cardiovascular events, and deaths in patients with CKD.

3.6. N-Acetyl-β-D-Glucosaminidase. As a lysosomal enzyme in the epithelial cells of renal proximal convoluted tubules, N-acetyl-β-D-glucosaminidase (NAG) cannot be filtered by the kidneys because of the very large molecular weight [52]. Patients with AKI, CKD, or HF have elevated NAG levels, and NAG is a biomarker that identifies cardiac or renal dysfunction in the general population and patients with urinary tract infection. NAG predicts prognosis in patients with AKI, CKD, or HF [56].

3.7. Interleukin-18. Interleukin-18 (IL-18) induces T-lymphocytes and natural killer cells to produce interferon in cell-mediated cytotoxic reaction [60]. IL-18 is a biomarker that identifies patients with AKI and predicts prognosis in these patients [61]. IL-18 may be specific to ischemic kidney injury rather than other kinds of AKI [62]. IL-18 not only has elevated levels and predicts mortality rates but also correlates with vascular stiffness and injury in patients with CKD. IL-18 may be a biomarker of vascular injury and may aggravate myocardial ischemia through mediating inflammation and necrosis. IL-18 increases in patients with HF and further increases as HF progresses [63]. IL-18 is related to increased mortality and reduced LVEF in patients with HF. IL-18 predicts cardiovascular prognosis in the general population [64].

3.8. Other Biomarkers. Homocysteine and uric acid have deleterious effects on cardiac function and structure and are significantly related to cardiovascular events and mortality [65]. Both of them are affected by renal function and serve as the biomarkers of incident CKD [49]. Meanwhile, patients with reduced urotensin II levels have increased cardiovascular mortality rates, and urotensin II may provide cardiovascular protection and predict cardiovascular deaths in patients with CKD [50]. Urotensin II correlates with ventricular function and vascular atherosclerosis in patients with CKD [66]. Additionally, RAAS plays a significant role in mediating the heart and kidney and promotes the development of CRS [1]. Aldosterone rather than renin is a significant biomarker of incident CKD [49].

4. Combination Use

Multimarker strategies may be critical to maximize clinical effects of biomarkers, and they have become increasingly prevalent in diagnosis, therapy, and prognosis of CRS [67].
Combining biomarkers may increase their accuracy, but the optimal combinations need to be defined [68]. The combination of biomarkers indicating hemodynamic stress (BNP) and cardiomyocyte necrosis (cTnI) is more likely to be clinically useful in HF [67]. ST2 provides complementary information to NT-proBNP and cTnI in cardiovascular risk stratification [69]. ST2 in combination with CRP is a valuable tool for identifying patients with HF at risk of death [70]. Combining cardiac and renal biomarkers in multimarker strategies may provide important information on the diagnosis, therapy, and prognosis of CRS [71]. The ideal multimarker strategies would measure relevant biomarkers simultaneously from a single biologic sample and report results in a way that integrates multiple biomarkers into simplified results (such as risk score) that could be applied directly to clinical decision-making [67].

5. Strength/Weakness

Comparison of these biomarkers can help in the application and selection of specific biomarkers in different clinical situations. Compared with NT-proBNP and cTnI, cystatin C has an additional ability to assess prognosis and stratify risk in patients with HF [72]. Compared with IL-18 and cystatin C, NGAL has a superior ability to predict the duration of AKI, renal replacement therapy, length of hospital stay, and mortality rates. Cystatin C has the highest specificity in biomarkers of AKI [70]. MR-proADM is superior to NT-proBNP in risk prediction of patients with HF. sST2 and BNP are equally useful for predicting all-cause mortality in patients with AHF. However, compared with BNP, sST2 is not useful as an aid in the diagnosis of AHF [73]. Compared with NT-proBNP, cTnI, and copeptin, MR-proADM is a stronger predictor of cardiovascular deaths in older patients of the emergency department [74]. However, both NT-proBNP and MR-proADM are regarded as equal for diagnosing HF according to European guidelines. It is very significant to note that detailed application and selection of these biomarkers remain a complex process. When these biomarkers aid in diagnosis, therapy, and prognosis of CRS, they must be interpreted within different clinical situations and not solely acted upon [68].

6. Future Perspectives

As one of the hottest topics, CRS and its biomarkers have received much attention in recent studies. However, there is still a scarcity of evidence about current biomarkers in CRS and little progress in novel biomarkers in CRS. Moreover, it is very difficult to further classify these biomarkers in each type of CRS due to lacking evidence and considerable overlap. In the future, more studies are needed to support current biomarkers and find novel biomarkers in each type of CRS. Although novel platforms, including genomics, proteomics, and metabolomics, are still under development, they have significant potential to explore biomarkers in CRS [68]. To explore and apply a biomarker in CRS, the following requirements should be considered: (1) identification and classification of CRS, (2) risk stratification and prognostic predication of patients with CRS, and (3) therapeutic guiding and monitoring of these patients [1].

7. Conclusion

Biomarkers are not only predictive in HF or renal diseases, but also useful in identifying cardiac dysfunction in renal diseases and renal injury in HF. Thus, they may be applied in order to identify patients with CRS and even assess prognosis and guide therapy in these patients. However, studies on biomarkers have just begun in CRS. Future studies are essential to observe current biomarkers and find novel biomarkers in CRS so as to improve diagnosis, therapy, and prognosis of CRS.

Disclosure

Shihui Fu and Shaopan Zhao are co-first authors. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Conflicts of Interest

The authors have declared that no conflicts of interest exist.

Acknowledgments

The authors are grateful to all the study participants for their participation in the study. This study was supported by grants from the Health Special Scientific Research Project of Chinese People’s Liberation Army (12BJZ34 and 14BJZ12), Sanya Medical and Health Science and Technology Innovation Project (2016YW21), and Clinical Scientific Research Supporting Fund of Chinese People’s Liberation Army General Hospital (2017FC-CXYY-3009).

References

[1] C. Ronco, P. McCullough, S. D. Anker et al., “Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative,” European Heart Journal, vol. 31, no. 6, pp. 703–711, 2010.
[2] K. Damman and J. M. Testani, “The kidney in heart failure: An update,” European Heart Journal, vol. 36, no. 23, pp. 1437–1444, 2015.
[3] “Expert Group on Biomarkers. Biomarkers in Cardiology-Part 2: In Coronary Heart Disease, Valve Disease and Special Situations,” Arquivos Brasileiros de Cardiologia Journal, vol. 104, no. 5, pp. 337–346, 2015.
[4] J. W. Pickering, M. P. than, L. Cullen et al., “Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis,” Annals of Internal Medicine, vol. 166, no. 10, pp. 715–724, 2017.
[5] S. Takashio, T. Nagai, Y. Sugano et al., “Persistent increase in cardiac troponin T at hospital discharge predicts repeat hospitalization in patients with acute decompensated heart failure,” PLoS ONE, vol. 12, no. 4, Article ID e0173336, 2017.
[6] S. L. Seliger, S. N. Hong, R. H. Christenson et al., "High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: MESA (Multi-Ethnic Study of Atherosclerosis)," Circulation, vol. 135, no. 16, pp. 1494–1505, 2017.

[7] V. Fridén, K. Starnberg, A. Muslimovic et al., "Clearance of cardiotropin T with and without kidney function," Clinical Biochemistry, vol. 50, no. 9, pp. 468–474, 2017.

[8] H. Yang, J. Liu, H. Luo et al., "Improving the diagnostic accuracy of acute myocardial infarction with the use of high-sensitive cardiotropin T in different chronic kidney disease stages," Scientific Reports, vol. 7, p. 41350, 2017.

[9] B. Morawiec, S. Fournier, M. Tapponnier et al., "Performance of highly sensitive cardiotropin T assay to detect ischaemia at PET-CT in low-risk patients with acute coronary syndrome: A prospective observational study," BMJ Open, vol. 7, no. 7, Article ID e014655, 2017.

[10] J. Franeková, L. Hošková, P. Sečn´ık et al., “The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnI in predicting prognosis and heart function after heart transplantation,” Clinical Chemistry and Laboratory Medicine, vol. 54, no. 2, pp. 339–344, 2016.

[11] S. Fu, L. Xie, D. Li, P. Ye, and L. Luo, “The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure,” Clinical Interventions in Aging, vol. 10, pp. 359–365, 2015.

[12] G. Giannakoulas, K. Dimopoulos, A. P. Bolger et al., “Usefulness of Natriuretic Peptide Levels to Predict Mortality in Adults With Congenital Heart Disease,” American Journal of Cardiology, vol. 105, no. 6, pp. 869–873, 2010.

[13] A. Mayr, I. Mair, M. Schocke et al., “Predictive value of NT-proBNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function,” International Journal of Cardiology, vol. 147, no. 1, pp. 118–123, 2011.

[14] O. F. AbouEzzeddine, P. M. McKie, C. G. Scott et al., “Biomarker-based risk prediction in the community,” European Journal of Heart Failure, vol. 18, no. 11, pp. 1342–1350, 2016.

[15] D. Farmakis, J. T. Parisis, V. Bistola et al., “Plasma B-type natriuretic peptide reduction predicts long-term response to losimendan therapy in acutely decompensated chronic heart failure,” International Journal of Cardiology, vol. 139, no. 1, pp. 75–79, 2010.

[16] A. Palazzuoli, M. Gallotta, I. Quattrini et al., “Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure,” Vascular Health and Risk Management, vol. 6, pp. 411–418, 2016.

[17] S. Fu, L. Luo, P. Ye et al., “The ability of NT-proBNP to detect chronic heart failure and predict all-cause mortality is higher in elderly Chinese coronary artery disease patients with chronic kidney disease,” Clinical Interventions in Aging, vol. 8, pp. 409–417, 2013.

[18] C. Chazot, M. Rozes, C. Vo-Van et al., “Brain Natriuretic Peptide: Is a Marker of Fluid Overload in Incident Hemodialysis Patients,” Cardiorenal Medicine, vol. 7, no. 3, pp. 218–226, 2017.

[19] P. Srisawasdi, S. Vanavan, C. Charoenpanichkit, and M. H. Kroll, “The effect of renal dysfunction on BNP, NT-proBNP, and their ratio,” American Journal of Clinical Pathology, vol. 133, no. 1, pp. 14–23, 2010.

[20] F. G. Hage, S. Oparil, D. Xing, Y.-F. Chen, M. A. McCrory, and A. J. Szalai, “C-reactive protein-mediated vascular injury requires complement,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 6, pp. 1189–1195, 2010.

[21] R.-I. Mincu, R. A. Jánosi, D. Vinereanu, T. Rassaf, and M. Totzeck, “Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis,” Scientific Reports, vol. 7, Article ID 41530, 2017.

[22] S. Kang, L.-Y. Fan, M. Chen, J. Li, and Z.-M. Liu, “Relationship of high-sensitivity C-reactive protein concentrations and systolic heart failure,” Current Vascular Pharmacology, vol. 15, no. 4, pp. 390–396, 2017.

[23] S. Fu, P. Ping, L. Luo, and P. Ye, “Deep analyses of the associations of a series of biomarkers with insulin resistance, metabolic syndrome, and diabetes risk in non-diabetic middle-aged and elderly individuals: Results from a Chinese community-based study,” Clinical Interventions in Aging, vol. 11, pp. 1531–1538, 2016.

[24] P. M. Ridker, J. E. Buring, N. Rifai, and N. R. Cook, “Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score,” The Journal of the American Medical Association, vol. 297, no. 6, pp. 611–619, 2007.

[25] L.-P. He, X.-Y. Tang, W.-H. Ling, W.-Q. Chen, and Y.-M. Chen, “Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: A meta-analysis of longitudinal studies,” Heart, vol. 96, no. 5, pp. 339–346, 2010.

[26] W. Li, L. Xiong, L. Fan et al., “Association of baseline, longitudinal serum high-sensitive C-reactive protein and its change with mortality in peritoneal dialysis patients,” BMC Nephrology, vol. 18, no. 1, article no. 211, 2017.

[27] K. Sharma, “Myeloperoxidase Activity and Oxidized Amino Acids as Biomarkers in Chronic Kidney Disease and Coronary Artery Disease,” American Journal of Nephrology, vol. 46, no. 1, pp. 71–72, 2017.

[28] P. Song, J. Xu, Y. Song, S. Jiang, H. Yuan, and X. Zhang, “Association of plasma myeloperoxidase level with risk of coronary artery disease in patients with type 2 diabetes,” Disease Markers, vol. 2015, Article ID 761939, 5 pages, 2015.

[29] O. Gedikli, A. Kiris, Y. Hosoglu, C. Karahan, and S. Kaplan, “Serum myeloperoxidase level is associated with heart-type fatty acid-binding protein but not Troponin T in patients with chronic heart failure,” Medical Principles and Practice, vol. 24, no. 1, pp. 42–46, 2015.

[30] F. Afshinnia, L. Zeng, J. Byun et al., “Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease,” American Journal of Nephrology, vol. 46, no. 1, pp. 73–81, 2017.

[31] E. Vorovich, B. French, B. Ky et al., “Biomarker predictors of cardiac hospitalization in chronic heart failure: A recurrent event analysis,” Journal of Cardiovascular Failure, vol. 20, no. 8, pp. 569–576, 2014.

[32] N. J. Hannan, F. C. Brownfoot, P. Cannon et al., “Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment,” Scientific Reports, vol. 7, no. 1, article no. 1819, 2017.

[33] J.-N. Boeckel, J. Oppermann, R. Anadol, S. Fichtlscherer, A. M. Zeiher, and T. Keller, “Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model,” Scientific Reports, vol. 6, Article ID 20812, 2016.

[34] D. Bolignano, A. Cabassi, E. Fiacchadori et al., “Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 10, pp. 1447–1456, 2014.
I . T . Klip, A . Voorset al., “Prognostic value of ST2 as a cardiovascular risk biomarker: from the bench to the bedside,” Journal of Cardiovascular Translational Research, vol. 6, no. 4, pp. 493–500, 2013.

J . Schmitz, A . Owyang, E . Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, vol. 23, no. 5, pp. 479–490, 2005.

L . B . Daniels and A . Bayes-Genis, “Using ST2 in cardiovascular patients: A review,” Future Cardiology, vol. 10, no. 4, pp. 525–539, 2014.

S . Manzano-Fernandez, T . Mueller, D . Pascual-Figal, Q . A . Truong, and J . L . Januzzi, “Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction,” American Journal of Cardiology, vol. 107, no. 2, pp. 259–267, 2011.

R . G . O’Malley, M . B . Bonaca, B . M . Scirica et al., “Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36),” Journal of the American College of Cardiology, vol. 63, no. 16, pp. 1644–1653, 2014.

M . Jougasaki and J . C . Burnett Jr., “Adrenomedullin: Potential in physiology and pathophysiology,” Life Sciences, vol. 66, no. 10, pp. 855–872, 2000.

N . G . Morgenhaler, J . Struck, C . Alonso, and A . Bergmann, “Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay,” Clinical Chemistry, vol. 51, no. 10, pp. 1823–1829, 2005.

I . T . Klip, A . A . Voors, S . D . Anker et al., “Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction,” Heart, vol. 97, no. 11, pp. 892–898, 2011.

M . Martin, S . Julia, and M . Alan, “The role of procalcitonin in acute heart failure patients,” SC Heart Failure, vol. 4, pp. 203–208, 2017.

N . Cvetinovic, A . M . Isakovic, M . Lainscak, H . Dungen, N . M . Nikolic, and G . Loncar, “Procalcitonin in heart failure:” Biomarkers in Medicine, vol. 11, no. 10, pp. 893–903, 2017.

E . Grace and R . M . Turner, “Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy,”Clinical Infectious Diseases, vol. 59, no. 12, pp. 1761–1767, 2014.

M . Iacoviello, M . Leone, V . Antoncecchi et al., “Evaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistances,” World Journal of Clinical Cases, vol. 3, no. 1, pp. 10–19, 2015.

C . S . Fox, P . Gona, M . G . Larson et al., “A multi-marker approach to predict incident CKD and microalbuminuria,” Journal of the American Society of Nephrology, vol. 21, no. 12, pp. 2143–2149, 2010.

A . Garoufi, S . Drapanioti, A . Marmarinos et al., “Plasma Urotensin II levels in children and adolescents with chronic kidney disease: A single-centre study,” BMC Nephrology, vol. 18, no. 1, article no. 113, 2017.

S . Fu, S . Zhou, L . Luo, and P . Ye, “Relationships of pancreatic beta-cell function with microalbuminuria and glomerular filtration rate in middle-aged and elderly population without type 2 diabetes mellitus: A chinese community-based analysis,” Clinical Interventions in Aging, vol. 12, pp. 753–757, 2017.

S . Fu, Y . Sun, L . Luo, and P . Ye, “Relationship of arterial compliance and blood pressure with microalbuminuria and mildly decreased glomerular filtration rate: A Chinese community-based analysis,” PLoS ONE, vol. 9, no. 6, Article ID e100133, 2014.

V . M . Van Deursen, K . Damman, A . A . Voors et al., “Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure,” Circulation: Heart Failure, vol. 7, no. 1, pp. 35–42, 2014.

C . G . Junghauer, C . Birner, B . Jung et al., “Kidney injury molecule-1 and N-acetyl-b-d-glucosaminidase in chronic heart failure: Possible biomarkers of cardioirenal syndrome,” European Journal of Heart Failure, vol. 13, no. 10, pp. 1104–1110, 2011.

J . M . Testani and W . H . W . Tang, “Biomarkers of acute kidney injury in chronic heart failure: What do the signals mean?” JACC: Heart Failure, vol. 1, no. 5, pp. 425–426, 2013.

B . Medic, B . Rovcanin, K . Savic Vujovic, D . Obrodovic, D . Duric, and M . Prostran, “Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations,” Current Medicinal Chemistry, vol. 23, no. 19, pp. 1981–1997, 2016.

P . Rafouli-Stergiou, J . Parissis, D . Farmakis et al., “Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction,” International Journal of Cardiology, vol. 182, no. C, pp. 74–76, 2015.

M . M . Gevorgyan, N . P . Voronina, N . V . Goncharova et al., “Cystatin C as a Marker of Progressing Cardiovascular Events during Coronary Heart Disease,” Bulletin of Experimental Biology and Medicine, vol. 162, no. 4, pp. 421–424, 2017.

B . Medic, B . Rovcanin, G . Basta Jovanovic, S . Radojevic-Škodrić, and M . Prostran, “Kidney Injury Molecule-1 and Cardiovascular Diseases: From Basic Science to Clinical Practice,” BioMed Research International, vol. 2015, Article ID 854070, 2015.

M . A . Brisco and J . M . Testani, “Novel Renal Biomarkers to Assess Cardiorenal Syndrome,” Current Heart Failure Reports, vol. 11, no. 4, pp. 485–499, 2014.

M . T . Wybraniec and K . Mizia-Stec, “Renalase and biomarkers of contrast-induced acute kidney injury,” Cardiorenal Medicine, vol. 6, no. 1, pp. 25–36, 2015.

S . G . Coca, A . X . Garg, H . Thiessen-Philbrook et al., “Urinary biomarkers of AKI and mortality 3 years after cardiac surgery,” Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 1063–1071, 2014.

T . H . Driver, R . Katz, J . H .Ix et al., “Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: The health, aging, and body composition (Health ABC) study,” American Journal of Kidney Diseases, vol. 64, no. 1, pp. 49–56, 2014.

C . Chen, X . Yang, Y . Lei et al., “Urinary biomarkers at the time of AKI diagnosis as predictors of progression of AKI among patients with acute cardioirenal syndrome,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 9, pp. 1536–1544, 2016.
S. Fu, L. Luo, P. Ye, and W. Xiao, “Multimarker analysis for new biomarkers in relation to central arterial stiffness and hemodynamics in a Chinese community-dwelling population,” *Angiology*, vol. 66, no. 10, pp. 950–956, 2015.

I. Albanese, S. S. Daskalopoulou, B. Yu et al., “The urotransin II system and carotid atherosclerosis: A role in vascular calcification,” *Frontiers in Pharmacology*, vol. 7, article no. 149, 2016.

L. A. Allen and G. M. Felker, “Multi-marker strategies in heart failure: Clinical and statistical approaches,” *Heart Failure Reviews*, vol. 15, no. 4, pp. 343–349, 2010.

J. Wang, G. J. Tan, L. N. Han et al., “Novel biomarkers for cardiovascular risk prediction,” *Journal of Geriatric Cardiology*, vol. 14, no. 2, pp. 135–150, 2017.

B. Dieplinger, M. Egger, M. Haltmayer et al., “Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study,” *Clinical Chemistry*, vol. 60, no. 3, pp. 530–540, 2014.

A. M. Dupuy, C. Curinier, N. Kuster et al., “Multi-marker strategy in heart failure: Combination of ST2 and CRP predicts poor outcome,” *PLoS ONE*, vol. 11, no. 6, Article ID e0157159, 2016.

R. R. J. van Kimmenade, J. L. Januzzi Jr., A. L. Baggish et al., “Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure. Redefining the Cardiorenal Interaction?” *Journal of the American College of Cardiology*, vol. 48, no. 8, pp. 1621–1627, 2006.

R. Pimenta González, P. Couto Comba, M. Rodríguez Esteban et al., “Incidence, Mortality and Positive Predictive Value of Type 1 Cardiorenal Syndrome in Acute Coronary Syndrome,” *PLoS ONE*, vol. 11, no. 12, p. e0167166, 2016.

T. Mueller, A. Gegenhuber, I. Leitner, W. Poelz, M. Haltmayer, and B. Dieplinger, “Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure,” *Clinica Chimica Acta*, vol. 463, pp. 158–164, 2016.

P. Bahrmann, M. Christ, B. Hofner et al., “Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department,” *European heart journal. Acute cardiovascular care*, vol. 5, no. 8, pp. 568–578, 2016.